Julie Green Sells 20,964 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 20,964 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the transaction, the insider owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Julie Green also recently made the following trade(s):

• On Tuesday, February 17th, Julie Green sold 19,663 shares of Invivyd stock. The shares were sold at an average price of $1.54, for a total transaction of $30,281.02.

Invivyd Price Performance

IVVD stock opened at $1.61 on Friday. The company’s 50 day simple moving average is $2.17 and its 200-day simple moving average is $1.75. Invivyd, Inc. has a 12 month low of $0.46 and a 12 month high of $3.07. The firm has a market capitalization of $375.32 million, a PE ratio of -3.43 and a beta of 0.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IVVD. Courier Capital LLC acquired a new stake in shares of Invivyd in the fourth quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd during the 4th quarter valued at $27,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Invivyd during the 2nd quarter worth $27,000. DRW Securities LLC purchased a new position in shares of Invivyd in the 4th quarter worth $27,000. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after acquiring an additional 28,146 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

IVVD has been the subject of a number of analyst reports. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Finally, HC Wainwright lifted their price target on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.